A 68-year-old woman with locally advanced cutaneous squamous cell carcinoma
This case series has been developed with the assistance of:
Dr Guilherme Rabinowits (Head & Neck and Cutaneous Medical Oncology, Head & Neck Disease Management Team Co-Leader, Miami Cancer Institute, Miami, Florida, USA)
Professor Ralf Gutzmer (Universitäts-Klinik für Dermatologie, Allergologie, Venerologie und Phlebologie, Johannes Wesling Klinikum Minden, Minden, Germany)
The information presented is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of their professional licence, experience and knowledge of the individual patient.
For full prescribing information, including indications, contraindications, warnings, precautions and adverse events, please refer to the approved product labelling. Please note that products may have different product labelling according to geographical location. Full prescribing information is available from the European Medicines Agency (ema.europa.eu) in the European Union (EU).
All characters and events depicted in this patient case simulation are entirely fictitious. Any similarity to actual events or persons, living or deceased, is purely coincidental. This patient case features one specific individual scenario; response to treatment(s) may vary from one patient to another.
This activity is intended for healthcare professionals. To proceed, please confirm that you are a healthcare professional.
Case 1 (MAT-GLB-2204824-v2.0-10/2023)
Case 2 (MAT-GLB-2204825-v2.0-10/2023)
Case 3 (MAT-GLB-2204826-v2.0-10/2023)
Case 4 (MAT-GLB-2204827-v2.0-10/2023)
Prescribing Information: For full Libtayo (cemiplimab) product information in the EU, please refer to the Summary of Product Characteristics (SmPC).
Modules
A 68-year-old woman with locally advanced cutaneous squamous cell carcinoma
An 81-year-old man with metastatic advanced cutaneous squamous cell carcinoma
A 67-year-old man with locally advanced basal cell carcinoma– Part 1
A 67-year-old man with locally advanced basal cell carcinoma – Part 2
